Antibiogram of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in patients with diabetes
Objective: To determine the antibiogram of Pseudomonas aeruginosa and Methicillin-resistant Staphylococcus aureus (MRSA) in patients with diabetes.
Methods: The study was carried out in the Microbiology Department of Clinical and Research Laboratory, Baqai Institute of Diabetology and Endocrinology (BIDE) from January 2012 to December 2012. All samples received in the laboratory were processed according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Identification of Pseudomonas aeruginosa and Methicillin-resistant Staphylococcus aureus (MRSA) was done and antimicrobial susceptibility pattern was determined by disc diffusion method.
Results: A total of 585 pathogens were isolated from 542 specimens of patients with diabetes. One hundred twenty one (20.68%) Pseudomonas aeruginosa and 25(4.27%) non-aeruginosa Pseudomonas were detected from 542 samples. Among 108 (18%) samples detecting the growth of Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA) were found in 42 (39%) samples. Pseudomonas aeruginosa showed marked susceptibility to imipenem (100%) followed by piperacillin / tazobactam (90.91%). All MRSA positive specimens were susceptible to vancomycin, but highly or completely resistant to the other antimicrobial drugs.
Conclusion: In the present study imipenem, piperacillin/tazobactam and sulbactam-cefoperazone were found to be the most effective drugs against Pseudomonas aeruginosa. The majority of MRSA were resistant to one or more than one antimicrobial drugs. Vancomycin and imipenem were the most effective drugsagainst Staphylococcus aureus and MRSA.
How to cite this:Sabir R, Alvi SFD, Fawwad A, Basit A. Antibiogram of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in patients with diabetes. Pak J Med Sci 2014;30(4):814-818. doi: http://dx.doi.org/10.12669/pjms.304.4755
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- There are currently no refbacks.